Journal of the American Society of Nephrology · 2016 · 99 citations · 30 references
MedicinePharmacologyPharmacotherapyRenal PathophysiologyRenal PharmacokineticsRenal PharmacotherapyChronic Kidney DiseaseHereditary Renal DiseasesPharmacokinetics In Renal ImpairmentRenal DiseaseRenal Function TestingRenal Function TestsClinical ProgressionEgfr DependencePlacebo-controlled Efficacy AssessmentPlasma Osmolality RegulationRenal Function CovariatesTolvaptan TherapyUrine OsmolalityVasopressin Therapy
The vasopressin-cAMP-osmolality axis is abnormal in autosomal dominant polycystic kidney disease (ADPKD). In the Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes 3:4 Trial, a 3-year randomized, placebo-controlled trial in adults, the vasopressin V2 receptor antagonist tolvaptan slowed ADPKD progression in patients with preserved GFR. Here, we investigated the determinants of baseline urine osmolality (Uosm) and its value as a severity marker of ADPKD, the factors influencing the response to tolvaptan, and whether change in Uosm associated with key trial end points. At baseline, lower Uosm independently associated with female sex, presence of hypertension, lower eGFR, higher total kidney volume (TKV), and higher age. Tolvaptan consistently reduced Uosm by 200-300 mOsm/kg over 36 months. The Uosm response to tolvaptan depended on baseline eGFR and Uosm. Subjects with greater change in Uosm experienced a significant reduction in clinical progression events. Among subjects receiving tolvaptan, those with a greater suppression of Uosm had slower renal function decline. Assessment at follow-up, off medication, revealed a significant decrease in Uosm in both placebo and treated groups. Tolvaptan significantly increased plasma osmolality, which returned to baseline at follow-up. In conclusion, baseline Uosm in ADPKD reflects age, renal function, and TKV, and baseline Uosm, eGFR, and TKV influence the effect of tolvaptan on Uosm. The greatest renal benefit occurred in subjects achieving greater suppression of Uosm, that is, those with better eGFR at baseline. These results support the link between vasopressin V2 receptor signaling and ADPKD progression.
30
Jessica M. Sontrop, Stephanie N. Dixon, Amit X. Garg et al. · American Journal of Nephrology · 2013 · 5.9K citations · Full text
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst et al. · New England Journal of Medicine · 2012 · 1.6K citations · Full text
Medicine, Nephrology, Pharmacology +14
Arlene B. Chapman, Olivier Devuyst, Kai‐Uwe Eckardt et al. · Kidney International · 2015 · 605 citations · Full text
Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease
Vicente E. Torres, Xiaofang Wang, Qi Qian et al. · Nature Medicine · 2004 · 481 citations
Medicine, Genetics, Nephrology +14